Contract Pharma Manufacturing News

1. Made Scientific Selected As Manufacturer For Columbia University's Autologous And Allogeneic NOVAKnee Program - A First-In-Class Living Biologic Total Knee Replacement 6/5/2026

   Made Scientific, Inc., a leading U.S.-based clinical- and commercial-stage cell therapy contract development and manufacturing organization (CDMO), today announced it has been selected as manufacturer for NOVAKnee, a first-in-class living biologic total knee replacement being developed by researchers at Columbia University's School of Engineering and Vagelos College of Physicians and Surgeons under the Advanced Research Projects Agency for Health (ARPA-H) Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program.

2. Stipple Bio Enters Multi-Target License Agreement With Lonza To Advance Precision Oncology ADC Therapies 6/4/2026

   Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), and Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced a multi-target licensing agreement to support the development of next-generation precision oncology ADC therapies.

3. Made Scientific And Pluristyx Launch Integrated iPSC Development & Manufacturing Partnership To Advance Next-Generation iPSC-Derived Cell Therapies 6/4/2026

   Made Scientific, Inc., a leading U.S.-based clinical- and commercial-stage cell therapy contract development and manufacturing organization (CDMO), and Pluristyx, a leading provider of RUO and GMP induced pluripotent stem cell (iPSC) platform technologies, today announced a strategic partnership to integrate Pluristyx Technology including GMP iPSC lines and derivative cell types, including induced natural killer (iNK) cells and induced mesenchymal stem cells (iMSCs), into Made Scientific's end-to-end CDMO offering for global cell and gene therapy innovators.

4. Veranova Appoints Dr. Bob Huang Vice President And General Manager Of West Deptford Site 6/3/2026

   Veranova today announced the appointment of Dr. Bob Huang as Vice President and General Manager for its West Deptford, New Jersey facility. He will lead site operations, advance strategic growth initiatives, and strengthen manufacturing excellence and customer delivery.

5. Rezon Bio Appoints Dr. Ralf Otto As Chief Operating Officer To Support Next Phase Of Growth And Operational Expansion 6/3/2026

   Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dr. Ralf Otto, as Chief Operating Officer (COO) effective June 1, 2026.

6. Everest Medicines Enters Into Exclusive Licensing Agreement With Travere Therapeutics For Civorebrutinib A Potential Best-In-Class BTK Inhibitor For Rare Kidney Diseases 6/2/2026

   Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia.

7. Bluejay Diagnostics And Argonaut Manufacturing Services Announce Strategic Partnership 6/2/2026

   Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) (NASDAQ: BJDX), a medical diagnostics company focused on near-patient testing for critical care, today announced a strategic partnership with Argonaut Manufacturing Services (“Argonaut”) to support the advancement of Bluejay’s Symphony™ platform.

8. Lifecore Biomedical Signs Agreement With New Biopharmaceutical Customer 6/2/2026

   Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed a manufacturing services agreement with a leading provider of ophthalmic disease management solutions.

9. Chime Biologics And Daewoong Pharmaceutical Enter Strategic Partnership To Advance Dupilumab Biosimilar Development And Commercialization In Global Markets 6/2/2026

   Chime Biologics, a global biologics CDMO dedicated to enabling partners’ success, and Daewoong Pharmaceutical, a leading South Korean pharmaceutical company, today announced the signing of a strategic partnership agreement for the development and manufacturing of a dupilumab biosimilar candidate referencing Dupixent.

10. Aragen To Manufacture Renaissance Pharma's FDA Fast Track mAb As Part Of Ongoing Strategic Collaboration 6/2/2026

    Aragen, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has successfully tech-transferred and manufactured the first commercial-scale GMP batches of Renaissance Pharma’s lead candidate, Daretabart – a humanized monoclonal antibody targeting GD2 for high-risk neuroblastoma – in just 9 months.